专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08613903B2 Humanized L243 antibodies 有权
公开(公告)号：US08613903B2
公开(公告)日：2013-12-24
申请号：US12556718
申请日：2009-09-10
申请人： David M. Goldenberg , Hans J. Hansen , Zhengxing Qu , Chien-Hsing Chang
发明人： David M. Goldenberg , Hans J. Hansen , Zhengxing Qu , Chien-Hsing Chang
IPC分类号： A61K38/43 , A61K45/00 , A61K51/00 , A61K39/00 , A61K39/395 , C07K16/30
CPC分类号： C07K16/2833 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2887 , C07K16/4241 , C07K19/00 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92
摘要： Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.

2. 发明授权

US08084583B2 RS7 antibodies 有权
标题翻译： RS7抗体
公开(公告)号：US08084583B2
公开(公告)日：2011-12-27
申请号：US12389503
申请日：2009-02-20
申请人： Serengulam V. Govindan , Zhengxing Qu , Hans J. Hansen , David M. Goldenberg
发明人： Serengulam V. Govindan , Zhengxing Qu , Hans J. Hansen , David M. Goldenberg
IPC分类号： C07K16/00
CPC分类号： A61K45/06 , A61K39/39558 , A61K51/1045 , A61K51/1051 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K2317/21 , C07K2317/24
摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
摘要翻译：本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。这些结合蛋白的另一个实施方案具有两个或更多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。

3. 发明授权

US08084029B2 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof 有权
公开(公告)号：US08084029B2
公开(公告)日：2011-12-27
申请号：US13090391
申请日：2011-04-20
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： A61K39/395
CPC分类号： C07K16/30 , A61K41/0095 , A61K47/6843 , A61K49/0002 , A61K51/1018 , A61K2039/505 , C07K16/18 , C07K16/3076 , C07K2317/24 , C07K2317/56 , G01N33/57484 , G01N33/689
摘要： The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.

4. 发明授权

US08017736B2 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof 有权
标题翻译：甲胎蛋白Immu31抗体和融合蛋白及其使用方法
公开(公告)号：US08017736B2
公开(公告)日：2011-09-13
申请号：US12359745
申请日：2009-01-26
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： C12P21/08
CPC分类号： C07K16/30 , A61K41/0095 , A61K47/6843 , A61K49/0002 , A61K51/1018 , A61K2039/505 , C07K16/18 , C07K16/3076 , C07K2317/24 , C07K2317/56 , G01N33/57484 , G01N33/689
摘要： The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.
摘要翻译：本发明提供人源化，嵌合和人抗甲胎蛋白抗体，融合蛋白及其片段。抗体，融合蛋白及其片段以及与其它合适抗体的组合可用于治疗和诊断肝细胞癌，肝母细胞瘤，生殖细胞肿瘤癌和其他产生AFP的肿瘤。

5. 发明授权

US07772373B2 Internalizing anti-CD74 antibodies and methods of use 有权
标题翻译：内化抗CD74抗体及其使用方法
公开(公告)号：US07772373B2
公开(公告)日：2010-08-10
申请号：US11867775
申请日：2007-10-05
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： C07K16/00
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
摘要翻译：本发明提供人源化，嵌合和人抗CD74抗体，CD74抗体融合蛋白，免疫缀合物，疫苗和结合CD74的双特异性，主要组织相容性复合体（MHC）II类不变链I 1可用于治疗 B细胞病变，B细胞恶性肿瘤，其他细胞与CD74反应的其他恶性肿瘤，以及自身免疫性疾病以及治疗和诊断方法的诊断。

6. 发明授权

US07501498B2 Alpha-fetoprotein Immu31 antibodies and fusion proteins 有权
标题翻译：甲胎蛋白Immu31抗体和融合蛋白
公开(公告)号：US07501498B2
公开(公告)日：2009-03-10
申请号：US11870627
申请日：2007-10-11
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： C07K16/00 , C12P21/08 , C12P21/04 , A61K39/395 , C07H21/04
CPC分类号： C07K16/30 , A61K41/0095 , A61K47/6843 , A61K49/0002 , A61K51/1018 , A61K2039/505 , C07K16/18 , C07K16/3076 , C07K2317/24 , C07K2317/56 , G01N33/57484 , G01N33/689
摘要： The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.
摘要翻译：本发明提供人源化，嵌合和人抗甲胎蛋白抗体，融合蛋白及其片段。抗体，融合蛋白及其片段以及与其它合适抗体的组合可用于治疗和诊断肝细胞癌，肝母细胞瘤，生殖细胞肿瘤癌和其他产生AFP的肿瘤。

7. 发明授权

US08574575B2 RS7 antibodies 有权
公开(公告)号：US08574575B2
公开(公告)日：2013-11-05
申请号：US13293608
申请日：2011-11-10
申请人： Serengulam V. Govindan , Zhengxing Qu , Hans J. Hansen , David M. Goldenberg
发明人： Serengulam V. Govindan , Zhengxing Qu , Hans J. Hansen , David M. Goldenberg
IPC分类号： A61K39/395
CPC分类号： A61K45/06 , A61K39/39558 , A61K51/1045 , A61K51/1051 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K2317/21 , C07K2317/24
摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

8. 发明申请

US20120141372A1 RS7 Antibodies 有权
标题翻译： RS7抗体
公开(公告)号：US20120141372A1
公开(公告)日：2012-06-07
申请号：US13293608
申请日：2011-11-10
申请人： Serengulam V. Govindan , Zhengxing Qu , Hans J. Hansen , David M. Goldenberg
发明人： Serengulam V. Govindan , Zhengxing Qu , Hans J. Hansen , David M. Goldenberg
IPC分类号： A61K39/395 , A61P31/00 , A61P37/02 , A61K51/10 , A61P35/00
CPC分类号： A61K45/06 , A61K39/39558 , A61K51/1045 , A61K51/1051 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K2317/21 , C07K2317/24
摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
摘要翻译：本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。这些结合蛋白的另一个实施方案具有两个或多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。

9. 发明申请

US20110195023A1 Internalizing Anti-CD74 Antibodies and Methods of Use 审中-公开
公开(公告)号：US20110195023A1
公开(公告)日：2011-08-11
申请号：US13047515
申请日：2011-03-14
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： A61K39/395 , A61K51/10 , A61K38/19 , A61K38/21 , A61K38/20 , A61P37/02 , A61P37/06 , A61P17/00 , A61P3/10 , A61P25/14
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.

10. 发明授权

US07902338B2 Anti-CD19 antibodies 有权
标题翻译：抗CD19抗体
公开(公告)号：US07902338B2
公开(公告)日：2011-03-08
申请号：US12266999
申请日：2008-11-07
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： C07K16/00 , C07K17/00 , C12P21/08
CPC分类号： C07K16/2803 , A61K38/00 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1069 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/2809 , C07K16/283 , C07K16/2833 , C07K16/2887 , C07K16/30 , C07K16/3061 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/92
摘要： The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a the substitution of serine for phenylalanine at Kabat residue 91 in the human framework region in the hA19 VH sequence.
摘要翻译：本发明提供了结合人B细胞标记的人源化，嵌合和人抗CD19抗体，抗-CD19抗体融合蛋白及其片段。此类抗体，融合蛋白及其片段可用于治疗和诊断各种B细胞病症，包括B细胞恶性肿瘤和自身免疫性疾病。在更具体的实施方案中，人源化抗CD19抗体可以包含设计用于改善蛋白质稳定性，抗体结合和/或表达水平的一个或多个框架区氨基酸取代。在特别优选的实施方案中，取代包括在hA19 VH序列的人框架区中的Kabat残基91处用丝氨酸取代苯丙氨酸。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式